|
|
Build Your Online Product Catalogs?
| Product Name: |
Setipiprant,ACT129968
|
| Supply Ability: |
1000 |
| Related proudcts |
setipiprant, |
| Specifications |
98% |
| Price Term: |
FOB,CIF |
| Port of loading: |
SHANGHAI |
| Minimum Order |
1g |
| Unit Price: |
$100 |
|
| Setipiprant was initially researched by Actelion as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly. |
| Company: |
Shanghai Angewchem Co.Ltd
|
| Contact: |
Mr. Dylan Zhang |
| Address: |
:No. 3377, Kang Xin Road, Pudong New Area, Shanghai |
| Postcode: |
201200 |
| Tel: |
+86-21-50762507 |
| Fax: |
18917157435 |
| E-mail: |
|
|
|
|
Home
